Reuters, which first broke the news of Allergan’s interest in Shire, citing a pair of unnamed sources, also broke the news that Shire rejected Takeda’s third, $66-per-share offer earlier today, which the Japanese company later confirmed.
Takeda’s most recent, £46.50-per-share bid (about $66.00) was comprised of £17.75 ($25.20) in cash to be paid in U.S. dollars and £28.75 ($40.80) worth of new Takeda shares; Shire estimated that the offer put its value at £44 billion ($62.44 billion).
The Japanese company’s first offers were for £44 ($62.44) and £45.50 ($64.57) per share, respectively. Its deadline under U.K. law falls on April 25.
($1 = £0.704501)
Updated on 4/19 to include Allergan’s latest statement.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.